Effectiveness of Lu177-PSMA in treatment of refractory thyroid papillary cancer.

Evaluating the theranostic application of Lu177-PSMA in management of refractory thyroid papillary cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230803059015N1

Enrollment

Registered

2023-08-14

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radio-iodine refractory papillary thyroid cancer.

Interventions

Intervention 1: Intervention group: The multidisciplinary tumor board will decide whether patients were eligible for the treatment with 177Lu-PSMA-617. Patients will be considered eligible if one or m

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with metastatic radio-iodine refractory papillary thyroid cancer Patients with baseline, WBC>3000, Hb>9, platelete .cont>70000, AST and ALT<5*nl limit and Cr<2*nl limit

Exclusion criteria

Exclusion criteria: Patients who refused to participate in the study Life-expectancy of 5*nl limit and Cr>2*nl limit

Design outcomes

Primary

Measure	Time frame
Serum thyroglobulin level. Timepoint: Monthly. Method of measurement: Blood sampling.;PSMA avid lesions. Timepoint: Before and after completing the treatment. Method of measurement: Diagnostic method with ??Ga-PSMA PET/CT or alternative imaging (Tc??m-PSMA).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab amirkhani

Esfahan University of Medical Sciences

Znbamirkhaninew@gmail.com+98 31 3236 6015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026